Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Telmisartan · 1 trial · 1 indication
Percent collagen I deposition is defined as the average % collagen stained in multiple uniform sized high magnification images in each sample. Change was absolute change defined as the Week 48 value minus the baseline value.
Percent collagen I deposition defined as percentage of fibrotic/collagen area to total area. Change was absolute change defined as the Week 48 value minus the baseline value.
| Arm | Type | Description |
|---|---|---|
| Arm A: Telmisartan | EXPERIMENTAL | - |
| Arm B: No Study Drug | NO_INTERVENTION | Participants received no study drug and followed the week 0-48 evaluation schedule. |
| Name | Type | Description |
|---|---|---|
| Telmisartan | DRUG | Participants received Telmisartan 40 mg daily during weeks 0-4 followed by telmisartan 80 mg daily during weeks 5-48. |
Step 1 Inclusion Criteria: * HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to Step 1 entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV a...
Top 20 of 28 competitors
Telmisartan is being studied for use in HIV-1 Infection. It is an investigational small molecule being developed by cbdMD, Inc. (YCBD) as a potential treatment to reduce AIDS-related fibrotic and inflammatory contributors in patients with HIV-1 infection. It is currently in Phase 2 clinical development.
Telmisartan is an angiotensin II receptor blocker that targets the angiotensin II type 1 receptor. By blocking this receptor, it may reduce fibrosis and inflammation associated with HIV-1 infection. This mechanism is being evaluated in the TRAFIC study for its potential to address HIV-related complications.
Telmisartan is being developed by cbdMD, Inc., a company traded under the ticker YCBD. The company is conducting clinical research to evaluate the drug's potential in treating HIV-1 infection. The development program is currently in Phase 2.
Telmisartan is in Phase 2 clinical development for HIV-1 Infection. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, with results informing the ongoing development program.
Telmisartan has one completed Phase 2 clinical trial, NCT01928927, titled 'Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)'. This trial enrolled 58 participants with HIV-1 Infection in the United States and Puerto Rico, and was a randomized, no-treatment controlled study.
Telmisartan is a generic name for an angiotensin II receptor blocker that is also marketed under brand names such as Micardis. In the context of this development program, it is being repurposed for HIV-1 Infection by cbdMD, Inc. under the same chemical entity.